Multi-Kinase Inhibitor with or without Atezolizumab in Previously Treated Liver Cancer
What is the Purpose of this Study?
We are doing this study to compare the effectiveness of atezolizumab + a multi-kinase inhibitor (either cabozantinib or lenvatinib) versus a multi-kinase inhibitor alone.
What is the Condition Being Studied?
Hepatocellular Carcinoma
Who Can Participate in the Study?
Adults who:
- Have hepatocellular carcinoma (a type of liver cancer)
- Received exactly 1 previous line of therapy, which must have been atezolizumab + bevacizumab
For more information about who can join this study, please contact the study team at john.d.gibbs@duke.edu.
Age Group
Adults
What is Involved?
If you choose to join this study, you will:
- Take one of the study drugs, either cabozantinib or lenvatinib, by mouth once per day
- Receive the study drug atezolizumab through an IV once every 3 weeks (if assigned)
- Return to the clinic every 3 weeks so we can monitor your health
- Give blood and urine for testing
- Get CT or MRI scans every 9 weeks
You may be on the study drugs for up to 2 years.
Study Details
Full Title
[ACCRU-GI-2008] A Phase II Randomized Study of Atezolizumab plus Multi-Kinase Inhibitor versus Multi-Kinase Inhibitor Alone in Subjects with Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab Plus Bevacizumab
Principal Investigator
Assistant Professor of Medicine
Protocol Number
IRB:
PRO00110227
NCT:
NCT05168163
Phase
Phase
II
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL
Participate
Call 919-668-1861
or email gi-oncology-cru@dm.duke.edu